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ABSTRACT
Introduction: To analyze the prevalence of alloantibodies in multiply transfused patients. 
Methods: This study was a retrospective, exploratory and descriptive study with a 
quantitative approach. The study sample comprised 185 patients transfused at a 
referral service in the city of Passo Fundo, Rio Grande do Sul, from January 2016 
to February 2018.
Results: Overall, the antibodies identified were as follows: anti-E in 47 patients 
(18%), anti-D and anti-K in 28 patients each (11%), anti-C in 21 patients (8.1%), and 
inconclusive antibody results in 23 patients (8.9%). Females were a majority (55.7%), 
mean age was 48.8 years and mean quantity of blood transfused was 7.2 bags. 
Cardiovascular disorders were the most common comorbidities, in 39 patients (21.2%), 
followed by oncological disorders, in 38 patients (18.4%).
Conclusion: Alloimmunization is an important and frequent clinical condition that 
increases the risk of hemolytic reactions and is associated with significant patient 
morbidity and mortality.
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INTRODUCTION
Alloimmunization is defined as an immune response to foreign antigens 
after exposure to genetically different cells or tissues1. The increases in life 
expectancy and consequent population aging, has led to a greater risk of 
developing chronic-degenerative and oncological diseases and this, in common 
with the need for more complex surgeries that can require blood transfusions, 
has led to an increased frequency of anti-erythrocyte alloantibodies not 
belonging to the ABO system in the elderly population (over 60 years), 
demanding greater care with ensuring blood compatibility2,3.
Chronic infectious and inflammatory diseases, neoplasms and myelodysplastic 
syndromes are chronic diseases that often require blood-based treatments, 
predisposing patients to alloimmunization. Moreover, there are also diseases 
such as hemoglobinopathies and autoimmune diseases that naturally predispose 
to alloimmunization, increasing rates of erythrocyte sensitization, to which 
multiparous women are also prone4.
It is extremely important to take precautions with phenotyping and pre-
transfusional compatibility testing for erythrocyte antigens, especially in the 
elderly population and those with critical comorbidities. Transfusion reactions 
in these patients can be significantly harmful, given the inherently reduced 
functional reserves in the elderly and the higher rate of concomitant comorbidities, 
which can compromise patients’ general health status and aggravate 
possible reactions. Therefore, if blood transfusion is really necessary, it is 
recommended that phenotypical red blood cells should be used, identifying 
at least the Rh system (antigens C, c, E, and e) and Kell (K antigen), which 
are most strongly involved in alloimmunization and transfusion reactions5,6.
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Alloantibodies may prove clinically significant in 
future transfusions or pregnancy. These antibodies 
can cause acute or delayed hemolytic transfusion 
reactions or hemolytic disease of the fetus and newborn. 
They can also provoke lengthy and costly investigations 
in the blood bank and delays in locating compatible 
units for future transfusions. Only a fraction of the 
alloantibodies formed are identified. As such, the 
morbidity and mortality burden of RBC alloimmunization 
is likely underestimated7.
This study was motivated by the facts outlined 
above. The objectives were to analyze the results 
of routine alloantibody testing performed by the 
Hemotherapy service at the Hospital São Vicente 
de Paulo (in the northern region of Rio Grande do 
Sul, Brazil), highlighting the prevalence rates of 
alloantibodies in transfused patients and correlating 
them with the patients’ preexisting pathologies.
METHODS
This study was a retrospective, exploratory 
and descriptive study using quantitative methods. 
The study sample comprised 185 patients transfused 
at a referral service in the city of Passo Fundo 
(RS, Brazil), from January 2016 to February 2018. 
The results were input to an Excel spreadsheet 
(Microsoft, United States). Statistical analysis of 
the data was performed using SPSS Statistics 20.0 
(IBM, United States). Qualitative variables were 
expressed as frequencies and percentages while 
quantitative variables were expressed as means ± 
standard deviations. The level of significance was 
set at 5% (p = 0.05). A total of 185 patients were 
included and no patients were excluded.
RESULTS
A total of 22,850 red blood cell transfusions 
were performed during the period analyzed. We 
identified 259 alloantibodies, found in 185 patients. 
Female patients accounted for 55.7% of the sample 
(103 patients), mean age was 48.8 years (± 21.1), with 
53.9% classified as elderly (102 patients). The most 
common pathologies associated with detection of 
alloantibodies were as follows: 39 patients (21.2%) 
had cardiovascular disorders, 38 patients (20.5%) 
had oncological pathologies, and 34 patients (18.4%) 
had infections and traumas. Other data are shown 
in Table 1. The mean blood transfusion count in this 
group of alloimmunized patients was 7.2 bags of blood 
components, with a standard deviation of + 10.4.
The antibodies identified were, in descending order 
of frequency: anti-E in 47 patients (18%), anti-D and 
anti-K in 28 patients each (11%), anti-C in 21 patients 
(8.1% ), anti-M in 14 patients (5.4%), anti-P1 in 12 
patients (4.6%), anti-c and anti-Lea in 11 patients 
each (4.2%), anti-Jka in 10 patients (3.9%), anti-S 
in 9 patients (3.5%), anti-Leb in 8 patients (3.1%), 
anti-Lua and anti-Dia in 7 patients each (2.7%), anti-Jkb 
and anti-Fya in 6 patients each (2.3%), anti-Cw in 4 
patients (1.5%), anti-s in 3 patients (1.2%), and anti-
Kpa and anti-e in 2 patients each (0.8%). The results 
for 23 patients (8.9%) were inconclusive, as shown 
in Table 2.
DISCUSSION
Alloimmunization is an adverse effect of exposure 
to erythrocyte antigens and is caused by genetic 
disparities between donor and recipient. Formation of 
antibodies against one or more of these antigens is 
one of the risks of blood transfusion and can elicit 
transfusional hemolytic reactions with severities 
ranging from mild, with reduced effectiveness of 
transfusion therapy, to extremely severe, with the 
potential to cause the transfused patient’s death8.
The risk of alloimmunization is dependent on 
the recipient’s exposure to the foreign antigen and 
its immunogenicity, defined as a given antigen’s 
ability to stimulate production of antibodies in a 
patient who is not an antigen carrier6. Some donors 
express antigens in a number of copies that is so 
low that alloantibodies are not create in the recipient. 
However, others may express larger numbers of copies 
of the antigen, forming alloantibodies after a single 
transfusion9. Nevertheless, exposure to non-self-
antigens is a necessary but not a sufficient condition 
of formation of alloantibodies. Genetic differences 
between blood donors and recipients, the dose and 
the form of administration, and the number and 
frequency of transfusions all directly impact on the 
alloimmunization risk10.
Alloimmunization is one cause of transfusion 
associated mortality, although mortality resulting 
directly from alloimmunization is relatively rare. 
More common transfusion-related complications 
of red blood cell (RBC) alloimmunization include 1) 
transfusion delays as new alloantibodies are being 
identified, 2) difficulties in locating compatible blood 
for highly alloimmunized individuals, and 3) delayed 
hemolytic or serologic reactions. Acute hemolytic 
transfusion reactions, though rare, are also possible 
in alloimmunized patients. However, in the absence of 
future transfusions, pregnancies, or transplantation, 
RBC alloantibodies are not inherently dangerous7.
Clinically significant erythrocyte alloantibodies 
develop in more than 30% of patients given multiple 
transfusions, which can represent serious problems 
in the case of long-term transfusional therapy. 
Alloimmunization increases as the number of 
blood units transfused rises and approximately 2 
to 9% of patients may develop new alloantibodies, 
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while anti-K formation appears to be increased in 
multiply transfused patients10. One study showed 
that 50% of the population studied who received 
more than 10 transfusions were alloimmunized, with 
alloimmunized patients receiving on average 6.2 
transfusions of packed red blood cells, whereas in 
non-alloimmunized patients the mean number of blood 
transfusion was 3.62. In our study, alloimmunized 
patients had received a mean of 7.2 (SD +10.4) bags 
of blood components.
When clinically significant non-ABO antibodies are 
detected in the plasma of patients requiring red blood 
cell transfusions, transfusion services must find and 
administer erythrocytes without the corresponding 
antigens. Thus, in transfusion medicine, much time 
and effort is spent on detection and identification 
of blood group antibodies and on selection of a 
compatible product. In addition to ABO, the most 
clinically important antibodies are those of the Rh, Kell, 
Duffy, and Kidd blood group systems.2 In a Chilean 
study, the most frequently identified alloantibodies 
were anti-E (30.8%), anti-K (26.9%), anti-D (7.7%), 
and anti-Fya (5.8%)7. In a Brazilian study, formation 
of anti-K was observed in 26.68% and antibodies 
against Rh system antigens were found in 20% 
of alloimmunized patients2. A Dutch study found 
anti-E alloantibodies in 34% of the sample, anti-K 
in 24.9%, anti-Fya in 9% and anti-c in 8.5% as the 
most prevalent alloantibodies10. In another Brazilian 
study, anti-E (22%), anti-D (13.18%), anti-K (11.75%), 
and anti-C (9.17%) were the most common11. In our 
series, the most frequently identified antibodies were: 
anti-E (18%), anti-D (11%), anti-K (11%), and anti-C 
(8.1%), while inconclusive antibody results were also 
prevalent (8.9%). These results confirm and are in 
agreement with Brazilian and international literature, 
showing the prevalence of antibodies with specificity 
for the Rh system and Kell antigen.
Additionally, some studies have shown that female 
patients have an increased risk of alloimmunization, 
mainly due to multiparity8. One study reports that 
red blood cell alloantibodies can be induced by 
pregnancy, being potentially harmful to fetuses 
and newborns. Fetal anemia, hyperbilirubinemia, 
and even fetal hydrops and death can result from 
maternal alloimmunization, with up to 1 in 300 to 1 
in 600 births affected12.
Some pathologies are also linked to a higher risk of 
alloimmunization, either due to the patient’s immune 
status or due to the need for greater quantities of blood 
transfusions. In one study it was demonstrated that 
there is a higher risk of alloimmunization in patients 
with malignancies and digestive bleeding, followed 
by kidney disease, heart surgery and traumas8. 
The risk of alloimmunization is also greater in patients 
with autoimmune diseases (16%) and myeloid 
diseases (15-59%), solid tumors (up to 10%), and 
transplant patients, especially liver tumors (4-23%)10. 
Another study reports that alloimmunization rates are 
around 44% in patients with hematological neoplasms 
such as myelodysplastic syndrome, 20% in patients 
with thalassemia, and 18.7% in people with sickle 
cell disease6. Alloimmunization and autoimmunity are 
also linked, with an association with alloimmunization 
in systemic lupus erythematosus, rheumatoid 
arthritis, and ulcerative colitis12. On the other hand, 
immunosuppressed patients with leukemia have 
lower rates of alloimmunization10,12.
It was demonstrated in another study that there 
is a greater probability that white rather than black 
or Asian individuals (regardless of Rh-D status) will 
respond to antibodies, as well as relatively high rates 
of red blood cell alloimmunization in patients with sickle 
cell disease (SCD)12. Patients with SCD have some 
of the highest rates of RBC alloimmunization of any 
population. This may be due in part to the relatively 
high transfusion burden of patients, and may also be 
due in part to the number of Rh variants (of D, E/e, 
or C/c) known to occur in patients of African descent.
However, some studies show no difference in the 
occurrence of alloimmunization when comparing by 
gender, age, or comorbid pathologies2,10. In our study, 
cardiovascular (21.2%), oncological (20.5%), infectious, 
and traumatic conditions (18.4%) were prevalent in 
patients with alloantibodies, while rheumatological 
diseases, chronic kidney disease, and anemia 
accounted for another 22.7% of the patients.
Knowledge of the clinical conditions that predispose 
to alloimmunization is important for two reasons: 
it can influence the treatment of a patient and can 
lead to a better understanding of the etiology of 
the transfusion reaction13. It is therefore necessary 
to evaluate previous surgery and past and current 
comorbidities, research the patient’s family history and, 
in female patients, ask questions about gestational 
history. The clinical circumstances surrounding RBC 
transfusion are thought to impact the likelihood of 
the recipient becoming alloimmunized. Patients 
transfused in their baseline states of health are 
thought to be less likely to become alloimmunized 
than patients transfused in a state of inflammation14. 
In contrast, having acute chest syndrome at the time 
of a transfusion is a significant risk factor for becoming 
alloimmunized15, as is having a viral illness or other 
inflammatory disorder16,17.
The clinical consequence of transfusing RBCs 
expressing an antigen against which a recipient has 
alloantibodies varies by situation. Some seemingly 
incompatible RBCs may continue to circulate in the 
transfusion recipient for the remainder of their lives. 
In contrast, other RBCs may be completely cleared 
within days after transfusion in the form of a delayed 
hemolytic transfusion reaction. In delayed hemolytic 
transfusion reaction, the clinical team may observe 
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fever, dark urine, or hemoglobin that drops back to the 
pre-transfusion level. Blood bank work-up may reveal 
a seemingly new antibody, which was likely present 
pre-transfusion but below the level of detection7.
Increases in life expectancy and technological 
developments have led to an increase in the number 
of people with chronic-degenerative diseases and to 
more complex surgeries that require greater amounts 
of blood transfusions. Thus, multiply transfused patients 
are highly likely to form erythrocyte alloantibodies alone 
or in combination, autoantibodies, and antibodies to 
low-incidence antigens7,11,12.
Judicious transfusion or transfusion avoidance is 
one strategy for preventing RBC alloimmunization. 
However, this is often not feasible. Matching for some 
blood group antigens is recommended for patients 
with SCD, to reduce formation of alloantibodies to 
matched immunogenic antigens such as D, C/c, 
E/e, and K9118.
CONCLUSION
Alloimmunization is an important and frequent 
clinical condition that increases the risk of hemolytic 
reactions and is associated with significant 
patient morbidity and mortality. It is an important 
possibility in multiply transfused patients, mainly 
among those with onco-hematological diseases, 
hemoglobinopathies, and chronic renal failure, 
among other pathologies and should always be 
remembered as a differential diagnosis.
Erythrocyte phenotyping for the antigens of the 
Rh (D, C, E, e), Kell (K), Duffy (Fya, Fyb), and Kidd 
(Jka, Jkb) systems is an important procedure and 
aims to offer the patient the blood group with the 
lowest possible antigenic rate. Signs and symptoms 
of transfusion reactions should be observed and 
the possibility of emergency procedures should 
be considered in cases of hemolytic reaction, 
excluding other types of transfusion reactions such 
as Transfusion-Related Acute Lung Injury (TRALI), 
transfusion-related anaphylaxis, and sepsis. 
Significant attention must be drawn to the 
elderly population, since they are more likely to 
have alloantibodies on account of previous blood 
transfusions, medical pathologies, and multiple 
pregnancies. Thus, clinical and transfusional history 
should be carefully investigated in order to minimize 
the risks of transfusion reactions, and when there is 
a risk that the patient is alloimmunized, transfusion of 
phenotyped blood components should be indicated.
Table 1: Distribution of pathologies in alloimmunized 
patients seen at the Hospital São Vicente de Paulo 
Hemotherapy Service 
Disease N %
Cardiovascular Diseases 39 21.2
Malignant Diseases 38 20.5





Rheumatological and Renal Diseases 30 16.
Benign Hematological Diseases 12 6.4
185 100%
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